Unknown

Dataset Information

0

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.


ABSTRACT: BACKGROUND:In the NAPOLI-1 Phase 3 trial, nal-IRI+5-fluorouracil and leucovorin (5-FU/LV) significantly improved median overall survival (6.1 vs 4.2 months, P=0.012) and progression-free survival (3.1 vs 1.5 months, P=0.0001) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma patients previously treated with gemcitabine-based therapy. This analysis evaluated between treatment differences in quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST). METHODS:Overall survival was partitioned into time with grade ?3 toxicity (TOX), disease progression (REL), and time without disease progression symptoms or grade ?3 toxicity (TWiST). Mean Q-TWiST was calculated by weighting time spent by a utility of 1.0 for TWiST and 0.5 for TOX and REL. In threshold analyses, utility for TOX and REL were varied from 0.0 to 1.0. RESULTS:Patients in nal-IRI+5-FU/LV (n=117) vs 5-FU/LV (n=119) had significantly more mean time in TWiST (3.4 vs 2.4 months) and TOX (1.0 vs 0.3 months) but similar REL (2.5 vs 2.7 months). In the base case, nal-IRI+5-FU/LV patients had 1.3 months (95% CI, 0.4-2.1; 5.1 vs 3.9) greater Q-TWiST (threshold analyses range: 0.9-1.6 months). CONCLUSIONS:Within NAPOLI-1, nal-IRI+5-FU/LV resulted in statistically significant and clinically meaningful gains in quality-adjusted survival vs 5-FU/LV alone.

SUBMITTER: Pelzer U 

PROVIDER: S-EPMC5482729 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.

Pelzer Uwe U   Blanc Jean-Frédéric JF   Melisi Davide D   Cubillo Antonio A   Von Hoff Daniel D DD   Wang-Gillam Andrea A   Chen Li-Tzong LT   Siveke Jens T JT   Wan Yin Y   Solem Caitlyn T CT   Botteman Marc F MF   Yang Yoojung Y   de Jong Floris A FA   Hubner Richard A RA  

British journal of cancer 20170328 10


<h4>Background</h4>In the NAPOLI-1 Phase 3 trial, nal-IRI+5-fluorouracil and leucovorin (5-FU/LV) significantly improved median overall survival (6.1 vs 4.2 months, P=0.012) and progression-free survival (3.1 vs 1.5 months, P=0.0001) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma patients previously treated with gemcitabine-based therapy. This analysis evaluated between treatment differences in quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST).<h4>Meth  ...[more]

Similar Datasets

| S-EPMC7774735 | biostudies-literature
| S-EPMC6813114 | biostudies-literature
| S-EPMC10242623 | biostudies-literature
| S-EPMC2409832 | biostudies-other
| S-EPMC10007927 | biostudies-literature
| S-EPMC7031242 | biostudies-literature
| S-EPMC4551155 | biostudies-literature
| S-EPMC4232740 | biostudies-literature
| S-EPMC3871512 | biostudies-literature
| S-EPMC7045240 | biostudies-literature